Table 1 Comparison of the baseline characteristics of the patients in the tirofiban and non-tirofiban groups
From: Local tirofiban infusion for remnant stenosis in large vessel occlusion: tirofiban ASSIST study
|  | Non-tirofiban group (n = 59) | Tirofiban group (n = 59) | P value |
|---|---|---|---|
Age, median (IQR) | 63 (55–75) | 71 (61–78) | 0.015 |
Female | 16 (27.1%) | 23 (39.0%) | 0.171 |
Prestroke mRS, median (IQR) | 0 (0–0) | 0 (0–0) | 0.438 |
Initial NIHSS, median (IQR) | 15 (12–21) | 14 (10–20) | 0.322 |
ASPECTS, median (IQR) | 8 (4.5–9.5) (n = 41) | 8 (6–9) (n = 46) | 0.530 |
Intravenous rtPA | 29 (49.2%) | 30 (33.9%) | 0.093 |
Target occlusion location | Â | Â | 0.766 |
 Terminal ICA | 9 (15.3%) | 8 (13.6%) |  |
 MCA M1 | 34 (57.6%) | 38 (64.4%) |  |
 MCA M2 | 2 (3.4%) | 3 (5.1%) |  |
 VBA | 14 (23.7%) | 10 (16.9%) |  |
Hypertension | 38 (64.4%) | 38 (64.4%) | > 0.999 |
Diabetes mellitus | 19 (32.2%) | 18 (30.5%) | 0.843 |
Dyslipidemia | 25 (42.4%) | 14 (23.7%) | 0.031 |
Atrial fibrillation | 12 (20.3%) | 9 (15.3%) | 0.470 |
Coronary disease | 3 (5.1%) | 4 (6.8%) | > 0.999a |
Smoking | 21 (35.6%) | 23 (39.0%) | 0.703 |
Prior antiplatelet | 6 (10.2%) | 13 (22.0%) | 0.080 |
Prior anticoagulant | 4 (6.8%) | 1 (1.7%) | 0.364a |